Brief: Recursion Pharmaceuticals Inc - Announces Roche's Exercise Of Option For Microglia Map - SEC Filing
29/10/2025 13:01
Recursion Pharmaceuticals Inc RXRX.O: RECURSION PHARMACEUTICALS INC - ANNOUNCES ROCHE'S EXERCISE OF OPTION FOR MICROGLIA MAP - SEC FILING RECURSION PHARMACEUTICALS INC - ROCHE TO PAY RECURSION $30 MILLION ACCEPTANCE FEE - SEC FILING Source text: [ID:n0001601830-25-000152] Further company coverage: RXRX.O
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million